Identification of Blood Serum Micro-RNAs Associated With Idiopathic and LRRK2 Parkinson's Disease

被引:126
|
作者
Botta-Orfila, Teresa [1 ]
Morato, Xavier [1 ]
Compta, Yaroslau [1 ,2 ]
Jose Lozano, Juan [3 ]
Falgas, Neus [2 ]
Valldeoriola, Francesc [1 ,2 ]
Pont-Sunyer, Claustre [1 ,2 ]
Vilas, Dolores [1 ,2 ]
Mengual, Lourdes [4 ]
Fernandez, Manel [1 ]
Luis Molinuevo, Jose [2 ,5 ]
Antonell, Anna [2 ,5 ]
Jose Marti, Maria [1 ,2 ]
Fernandez-Santiago, Ruben [1 ]
Ezquerra, Mario [1 ]
机构
[1] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Invest Enfermedades Neurodegenerat CIBERNED, Lab Neurodegenerat Disorders,Dept Neurol, E-08036 Barcelona, Catalonia, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Movement Disorders Unit,Dept Neurol, Barcelona, Catalonia, Spain
[3] CEK, CIBEREHD, Barcelona, Catalonia, Spain
[4] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Lab & Dept Urol, E-08036 Barcelona, Catalonia, Spain
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Alzheimers Dis & Other Cognit Disorders Unit, Neurol Serv, E-08036 Barcelona, Catalonia, Spain
关键词
Parkinson's disease; biomarker; blood; miRNAs; CIRCULATING MICRORNA; EXPRESSION ANALYSIS; CLINICAL-DIAGNOSIS; ALZHEIMERS-DISEASE; PROTEIN; BIOMARKERS; SIGNATURES; MUTATIONS; NEURONS; CANCER;
D O I
10.1002/jnr.23377
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Blood-cell-free circulating micro-RNAs (miRNAs) have been proposed as potential accessible biomarkers for neurodegenerative diseases such as Parkinson's disease (PD). Here we analyzed the serum levels of 377 miRNAs in a discovery set of 10 idiopathic Parkinson's disease (IPD) patients, 10 PD patients carriers of the LRRK2 G2019S mutation (LRRK2 PD), and 10 controls by using real-time quantitative PCR-based TaqMan MicroRNA arrays. We detected candidate differentially expressed miRNAs, which were further tested in a first validation set consisting of 20 IPD, 20 LRRK2 PD, and 20 control samples. We found four statistically significant miRNAs that were downregulated in either LRRK2 or IPD (miR-29a, miR-29c, miR-19a, and miR-19b). Subsequently, we validated these findings in a third set of samples consisting of 65 IPD and 65 controls and confirmed the association of downregulated levels of miR-29c, miR-29a, and miR-19b in IPD. Differentially expressed miRNAs are predicted to target genes belonging to pathways related to ECM-receptor interaction, focal adhesion, MAPK, Wnt, mTOR, adipocytokine, and neuron projection. Results from our exploratory study indicate that downregulated levels of specific circulating serum miRNAs are associated with PD and suggest their potential use as noninvasive biomarkers for PD. Future studies should further confirm the association of these miRNAs with PD. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1071 / 1077
页数:7
相关论文
共 50 条
  • [41] LRRK2 as a therapeutic target in Parkinson's disease
    Tan, E. K.
    Schapira, A. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (04) : 545 - 546
  • [42] LRRK2 and the Endolysosomal System in Parkinson's Disease
    Erb, Madalynn L.
    Moore, Darren J.
    JOURNAL OF PARKINSONS DISEASE, 2020, 10 (04) : 1271 - 1291
  • [43] The Cell Biology of LRRK2 in Parkinson's Disease
    Usmani, Ahsan
    Shavarebi, Farbod
    Hiniker, Annie
    MOLECULAR AND CELLULAR BIOLOGY, 2021, 41 (05)
  • [44] Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2
    Singh, Ranjan K.
    Soliman, Ahmed
    Guaitoli, Giambattista
    Stoermer, Eliza
    von Zweydorf, Felix
    Dal Maso, Thomas
    Oun, Asmaa
    Van Rillaer, Laura
    Schmidt, Sven H.
    Chatterjee, Deep
    David, Joshua A.
    Pardon, Els
    Schwartz, Thomas U.
    Knapp, Stefan
    Kennedy, Eileen J.
    Steyaert, Jan
    Herberg, Friedrich W.
    Kortholt, Arjan
    Gloeckner, Christian Johannes
    Versees, Wim
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (09)
  • [45] Rab29 activation of the Parkinson's disease-associated LRRK2 kinase
    Purlyte, Elena
    Dhekne, Herschel S.
    Sarhan, Adil R.
    Gomez, Rachel
    Lis, Pawel
    Wightman, Melanie
    Martinez, Terina N.
    Tonelli, Francesca
    Pfeffer, Suzanne R.
    Alessi, Dario R.
    EMBO JOURNAL, 2018, 37 (01) : 1 - 18
  • [46] The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease
    DeBroff, Jake
    Omer, Nurit
    Cohen, Batsheva
    Giladi, Nir
    Kestenbaum, Meir
    Shirvan, Julia C.
    Cedarbaum, Jesse M.
    Gana-Weisz, Mali
    Goldstein, Orly
    Orr-Urtreger, Avi
    Mirelman, Anat
    Thaler, Avner
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (04): : 606 - 616
  • [47] Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk
    Lake, Julie
    Reed, Xylena
    Langston, Rebekah G.
    Nalls, Mike A.
    Gan-Or, Ziv
    Cookson, Mark R.
    Singleton, Andrew B.
    Blauwendraat, Cornelis
    Leonard, Hampton L.
    MOVEMENT DISORDERS, 2022, 37 (01) : 95 - 105
  • [48] New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease
    De, Surya K.
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (33) : 5477 - 5480
  • [49] Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease
    Greggio, Elisa
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1058 - 1062
  • [50] LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting
    Xiong, Yulan
    Yu, Jianzhong
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (10) : 982 - 996